Skip to main content

Table 3 High level of plasma sPLA2-IIa predicts lung cancer

From: Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules

Plasma sPLA2-IIa < 2.4 ng/ml > 2.4 ng/ml Total case# %Senstivity %Specificity
Table 3a: Determination of plasma sPLA2-IIa to predict lung cancer by ROC analysis.  
BNLCC lung cancer vs. benign SPN      
Benign SPN 24 5 29   86
Lung cancer 50 46 96 48  
Stage 1 lung cancer 24 20 44 45  
Stage 2 lung cancer 6 12 18 67  
GELCC lung cancer vs. benign SPN      
Lung cancer 16 28 44 64  
Table 3b: Combined sPLA2-IIa, CEA, and Cyfra21.1 blood tests increase the sentisitivity
to predict lung cancer.
sPLA2-IIa < 2.4 ng/ml > 2.4 ng/ml    
CEA < 6.0 ng/ml > 6.0 ng/ml Total case# %Senstivity %Specificity
Cyfra21.1 < 3.3 ng/ml > 3.3 ng/ml    
BNLCC lung cancer vs. benign SPN      
Benign SPN 22 7 29   76
Lung cancer 36 60 96 63  
Stage 1 lung cancer 18 26 44 59  
Stage 2 lung cancer 5 13 18 72  
CEA < 6.0 ng/ml > 6.0 ng/ml Total case# %Senstivity %Specificity
BNLCC lung cancer vs. benign SPN      
Benign SPN 28 1 29   97
Lung cancer 77 19 96 20  
Cyfra21.1 < 3.3 ng/ml > 3.3 ng/ml Total case# %Senstivity %Specificity
BNLCC lung cancer vs. benign SPN      
Benign SPN 27 2 29   93
Lung cancer 83 13 96 14